LSI is Officially Heading to Singapore — Register for LSI Asia '25 Today

September Emerging Medical Technologies Report

Published January 2012 | 15 Pages | 30 Exhibits |


Order individually or subscribe and get a complete intel platform.


This report includes details on 30 emerging medical technology companies that have been identified by LSI's in-house research team in September 2012.

All companies include technology, market(s), key executive, and contact information.

Coverage includes innovations in a broad spectrum of medical technology areas including:
- Aesthetics/Dermatology Companies
- Biomaterials Companies
- Biotechnology/Cell Therapy Companies
- Cardiovascular Companies
- Dental Companies
- Diagnostics Companies
- Drug Delivery Companies
- Endocrine Companies
- Gastroenterology Companies
- Gynecology/Women's Health Companies
- Imaging Companies
- Neurology Companies
- Oncology Companies
- Ophthalmology Companies
- Orthopedics Companies
- Pain Management Companies
- Patient Management/Monitoring Companies
- Pharmaceutical Companies
- Respiratory Companies
- Spine Companies
- Surgery Companies
- Urology Companies
- Vascular Companies
- Wound Management Companies

This report is included in LSI's Emerging Medical Technologies® Database.

Table of Contents


•1-Automated robotic delivery system that can securely transport one patient's prescription or an entire unit's scheduled doses on-demand from the pharmacy to the nurses' station and 2-A web-based medication tracking system that uses a combination of passive RFID, barcodes, biometrics, remote monitoring, and/or secure delivery carts to keep the pharmacy in touch with all orders, while meeting all compliance regulations
•Strip-based diagnostic test that will quickly and cost-effectively provide a definitive determination of whether a patient has suffered a cerebrospinal fluid leak as a result of surgery or trauma
•Small molecule that increases the natural production of erythropoietin (EPO) and causes a controlled, gradual rise in hemoglobin in patients with anemia
•Low-cost, high-value terpenes as therapeutics for infectious & cardiovascular diseases, oncology, and metabolic disorders
•Proteomics-based biomarker discovery that leads to superior data, better results, and improved diagnostics
•Tests that measure and analyze important genomic variants affecting the metabolism and response to behavioral health medications in individual patients
•Non-invasive, continuous monitor for the early detection of cerebral fluid accumulation due to stroke, traumatic brain injury (TBI), or brain surgery
•Formulation platform technology that provides tamper-resistant extended release drug delivery, for the treatment of chronic pain
•Interatrial Septal Device (IASD) for the treatment of congestive heart failure (CHF)
•Molecular diagnostic tests to target rare forms of cancer, including pediatric cancers
•Next-generation synthetic bone graft substitutes with optimized handling, reliability, and consistent surgical performance; for use in a broad range of non-load bearing osseous repair defects
•Implantable, programmable pump designed to deliver therapeutic drugs into the spine, for the treatment of chronic intractable pain and the management of severe spasticity
•Device for the treatment of chronic cardiovascular disease
•Externally delivered ultrasound energy to ablate the renal nerves, as a non-invasive, single-treatment, non-pharmacological approach to control hypertension
•Adeno-associated virus (AAV) delivered follistatin protein that is safer and more targeted, to increase muscle strength and improve the quality of life of muscular dystrophy patients
•1-Tests for preimplantation genetic diagnosis (PGD) performed during in-vitro fertilization in order to select embryos with the highest probability of becoming healthy children; 2-Conception testing following miscarriage in order to understand the cause; and 3-Non-invasive prenatal testing to determine paternity or detect genetic disease
•New class of pentraxin therapeutics to treat rare fibrotic diseases, including: idiopathic pulmonary fibrosis (IPF), myelofibrosis, and fibrovascular retinal diseases
•Technology that works by measuring and analyzing the light reflected off of the skin to make an accurate pressure ulcer (PU) diagnosis regardless of skin color and independent of the clinician's skill level
•Compounds that possess a low risk of side effects, for central nervous system (CNS) disorders, including: schizophrenia, major depressive disorder (MDD), pain, traumatic brain injury (TBI), multiple sclerosis (MS), autism (Fragile X), anesthesia, and post-traumatic stress disorder (PTSD)
•Suture delivery device that has the potential to transform certain open surgical procedures, traditionally performed in the operating room, into more cost-effective procedures that can be performed in the catheterization lab, where only a small piece of suture is left behind
•Molecular diagnostic assays that will enable new paradigms in the treatment of diseases as diverse as infection, auto-immune disease, and cancer
•Disruptive technology with the potential to transform the standard of care for root canal procedures
•Small molecule drug candidates that modulate the sphingosine 1-phosphate (S1P) pathway in new and different ways, for the treatment of diseases such as cancer and fibrosis
•Highly selective qPCR reagents that provide an increased level of confidence and convenience for the detection of key cancer mutations
•Sustained release drugs for treating tardive dyskinesia (TD) and other movement disorders
•Platform for surgery to be performed through a patient's mouth or other natural orifices, rather than the abdomen, for less pain, shorter hospital stays, reduced risk of wound infection, and no external scars
•Ultrasound system, specifically for patients with dense breast tissue, where the effectiveness of mammography may be limited
•Unique retractable over-the-wire guidance system to assist in optimal atraumatic intravenous catheter delivery, designed for greater first attempt success and increased dwell times
•Innovative platform for the rapid generation of monoclonal antibody therapeutics for the treatment cancer and age-related macular degeneration (AMD)
•Physiological and biomechanical monitoring technology that enables loved ones to stay in their home longer while family, friends, and medical practitioners can remotely monitor their physiological state

Work with us

Accelerate your business

We’re here to help you make smarter decisions and form stronger partnerships through curated events, independent market intelligence products and services, and digital-forward media.